Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.40%
$7.79
0% positive prob.
5-Day Prediction
-4.70%
$7.53
0% positive prob.
20-Day Prediction
-4.20%
$7.57
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | -1.40% | -4.70% | -4.20% | 100.0% | Pending |
| Q2 2026 | SELL | -1.68% | -5.11% | -3.67% | 99.7% | Pending |
| Q1 2026 | SELL | -1.65% | -5.41% | -1.85% | 99.9% | -2.09% |
| Q4 2025 | SELL | -1.80% | -5.99% | -1.75% | 100.0% | +2.20% |
SEC 8-K filings with transcript text
Nov 9, 2026 · 100% conf.
1D
-1.40%
$7.79
Act: -8.80%
5D
-4.70%
$7.53
20D
-4.20%
$7.57
2 ofix-ex99_1.htm
Exhibit 99.1
News Release
Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance
LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines.
Third Quarter 2026 Highlights
• Total reported net sales of $207.9 million, representing an increase of 1% on a reported basis and 2% on a pro forma constant currency basis compared with the prior year period.
• Reported net loss of $(6.1) million and non-GAAP adjusted EBITDA of $26.0 million.
• Revised full-year 2026 pro forma net sales guidance to $825 million to $830 million and non-GAAP adjusted EBITDA guidance to $86 million to $88 million, reflecting third-quarter performance and the anticipated fourth quarter impact of actions to improve U.S. Spine execution, instrument set availability and asset productivity.
• Global Spine Fixation1 net sales increased 1% on a reported and constant currency basis compared with the prior year period.
• Global Limb Reconstruction net sales increased 8% on a reported basis and 9% on a constant currency basis compared with the prior year period.
• Therapeutic Solutions net sales increased 4% compared with the prior year period.
“Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance,” said Massimo Calafiore, President and Chief Executive Officer. “In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities. Our revised guidance reflects third-quarter performance and the near-term impact of these actions, which are intended to build a stronger foundation for sustainable growth, profitability and cash generation.”
1 Spine Fixation is comprised of the Company’s Spinal Implants product category, excluding motion preservation product offerings.
1
Financial Results Overview
Third Quarter 2026 Net Sales and Financial Results
The following table presents net sales by product category and reporting segment on a pro forma basis, removing the effects of the Company’s discontinued M6 product lines:
Three Months Ended September 30,
(Unaudited, U.S. Dollars, in millions)
2026
2025
Change
Constant Currency Change
Therapeutic Solutions
$
64.0
$
61.2
4.5
%
4.5
%
Spinal Implants, Biologics and Enabling Technologies*
107.4
108.6
(1.1
%)
(1.1
%)
Global Spine*
171.4
169.8
0.9
%
0.9
%
Global Limb Reconstruction
36.4
33.6
8.5
%
9.4
%
Pro forma net sales*
207.8
203.4
2.2
%
2.3
%
Impact from discontinuation of M6 product lines
0.1
2.2
(96.8
%)
(96.8
%)
Reported net sales
$
207.9
$
205.6
1.1
%
1.2
%
* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.
For the third quarter of 2026, net sales were $207.9 million, representing an increase of 1.1% on a reported basis and 2.3% on a non-GAAP pro forma constant currency basis compared to third quarter 2025.
For the third quarter of 2026, GAAP gross margins were 70.5% and were 70.7% on a non-GAAP adjusted basis.
For the third quarter of 2026, reported net loss was $(6.1) million, or $(0.15) per share compared to reported net loss of $(22.8) million, or $(0.57) per share in the prior year period. Non-GAAP adjusted EBITDA was $26.0 million, or 12.5% of pro forma net sales, in the third quarter of 2026, compared to non-GAAP adjusted EBITDA of $24.6 million, or 12.1% of pro forma net sales, in the third quarter of 2025. The year-over-year increase primarily reflected continued cost discipline and resource alignment initiatives, partially offset by lower Spine revenue, unfavorable geographic mix and the related reduction in operating leverage.
Liquidity
Cash, cash equivalents, and restricted cash totaled $86.9 million at September 30, 2026, compared with $104.4 million at June 30, 2026. The sequential change primarily reflected working capital timing.
Business Outlook
Orthofix is revising its full-year 2026 net sales and adjusted EBITDA guidance. Both guidance ranges assume current foreign currency exchange rates.
• Net sales are now expected to range
Aug 5, 2026 · 100% conf.
1D
-1.68%
$10.25
Act: +1.73%
5D
-5.11%
$9.89
20D
-3.67%
$10.04
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1786365368.ca22893a
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 5, 2026 · 100% conf.
1D
-1.65%
$12.23
Act: -2.01%
5D
-5.41%
$11.77
Act: -2.09%
20D
-1.85%
$12.21
Act: -21.86%
2 ofix-ex99_1.htm
Exhibit 99.1
News Release
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine
Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
LEWISVILLE, Texas — May 5, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6™ product lines.
Highlights
• First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a constant currency basis, reflecting steady execution during the final stages of distributor transitions, with further improvement expected as productivity increases.
• Global Spine Fixation1 delivered reported net sales growth of 6% and constant currency growth of 6% compared to the prior year period, including U.S. Spine Fixation growth of 4%, driven by enhanced commercial focus, deeper procedural penetration, and continuing benefits from distributor transition initiatives.
• Therapeutic Solutions (formerly Bone Growth Therapies) achieved year-over-year net sales growth of 5%, supported by continued demand across the portfolio and effective commercial execution.
• Global Limb Reconstruction reported net sales growth of 10% and constant currency growth of 3% compared to the prior year period, reflecting continued demand for core fixation and reconstruction systems.
• First quarter 2026 reported net loss of $(20.9) million and non-GAAP pro forma adjusted EBITDA of $9.7 million, reflecting impacts from geography mix and commercial transitions.
“Our first-quarter results reflect steady execution as we complete key spine commercial channel actions and sharpen our strategic focus,” said Massimo Calafiore, President and Chief Executive Officer. “While the quarter continued to absorb the impact of these transitions, most notably in biologics, we saw improved commercial focus and operating discipline as the quarter progressed.”
Mr. Calafiore continued, “Importantly, distributor transitions are now largely behind us, providing greater visibility for the remainder of the year. As we move through 2026, our priorities are clear: driving more consistent commercial execution, advancing targeted innovation across our portfolio, and expanding margins through disciplined operational management. With recent spine leadership changes, a renewed focus on advancing our biologics portfolio, and planned product launches later this year, we believe Orthofix is positioned to deliver more consistent growth, expand margins, and generate strong free cash flow to support long-term shareholder value.”
1 Spine Fixation is comprised of the Company’s Spinal Implants product category, excluding motion preservation product offerings.
1
Financial Results Overview
First Quarter 2026 Net Sales and Financial Results
The following table provides net sales by major product category and by reporting segment on a pro forma basis, removing the effects of the Company’s discontinued M6 product lines:
Three Months Ended March 31,
(Unaudited, U.S. Dollars, in millions)
2026
2025
Change
Constant Currency Change
Therapeutic Solutions
$
57.8
$
55.1
4.9
%
4.9
%
Spinal Implants, Biologics and Enabling Technologies*
105.8
104.3
1.4
%
1.4
%
Global Spine*
163.6
159.4
2.6
%
2.6
%
Global Limb Reconstruction
32.8
29.8
10.2
%
3.0
%
Pro forma net sales*
196.4
189.2
3.8
%
2.7
%
Impact from discontinuation of M6 product lines
0.3
4.4
(94.2
%)
(94.5
%)
Reported net sales
$
196.7
$
193.6
1.6
%
0.4
%
* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.
For the first quarter of 2026, net sales were $196.7 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales were $196.4 million, excluding sales from M6 discs, representing an increase of 1.6% on a reported basis and 2.7% on a non-GAAP pro forma constant currency basis compared to first quarter 2025.
For the first quarter of 2026, GAAP gross margins were 70.9% and were 70.7% on
This page provides Orthofix Medical Inc. (DE) (OFIX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on OFIX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.